Sage Cognitive Performance Randomized Trial: What the Evidence Says

Quick Answer

Sage Cognitive Performance Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are systematic review, randomized trial, so conclusions should be framed as evidence-aware guidance rather than medical advice.

Key Takeaways

• This page is generated only from sources stored in the Migaku evidence knowledge base.
• Current evidence mix: 1 systematic review, 1 randomized trial.
• Claims should be interpreted with the source type, study design, population, and publication date in mind.
• This article is educational and does not replace care from a qualified clinician.

Evidence Map

What The Sources Report

• This gap underscores the rationale for systematically reviewing the available evidence, not only to consolidate findings but also to highlight the scope and limitations of current approaches in managing cognitive decline in AD. [Krishna Dwivedi (2026); evidence level 1]
• Herein lies the importance of systematic reviews by synthesising disparate lines of evidence; such reviews can critically evaluate the efficacy and safety of these complementary interventions, identify gaps in the current literature and guide future clinical applications. [Krishna Dwivedi (2026); evidence level 1]
• Physiological, psychosocial, and neuroendocrine changes associated with aging lead to substantial alterations in sleep architecture. [Ede Sarıkaya Belçim (2026); evidence level 2]
• ,, Pharmacological interventions for sleep problems in older adults are associated with important risks, including falls, cognitive impairment, and dependency.Consequently, safer and more sustainable non-pharmacological approaches have gained increasing attention. [Ede Sarıkaya Belçim (2026); evidence level 2]

How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

Practical Interpretation

There is at least one systematic-review style source in the current set, so it deserves more weight than single-study evidence. There is trial evidence in the current set, but population and intervention details still matter. For sage cognitive performance randomized trial, the next editorial step is to add more targeted sources and separate strong findings from early or indirect evidence.

Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

References

• Krishna Dwivedi (2026). Mind–Body Interventions as Modulators of Neural Connectivity and Cognition in Individuals at Risk for Alzheimer’s Disease: A Systematic Review. DOI: 10.1177/09727531261441080. PMCID: PMC13226303. PMID: 42238355. License: https://creativecommons.org/licenses/by-nc/4.0/ https://creativecommons.org/licenses/by-nc/4.0/ https://us.sagepub.co.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13226303/
• Ede Sarıkaya Belçim (2026). Effects of inhaled aromatherapy on sleep quality and cognitive function in older adults: a randomised controlled trial. DOI: 10.1093/gerona/glag105. PMCID: PMC13199057. PMID: 42011111. License: https://creativecommons.org/licenses/by-nc-nd/4.0/ https://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13199057/

Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.